Black Diamond Gets The Gift Of Time In License Pact With Servier
Servier takes a Phase I rationally designed cancer candidate for $70m up front, while Black Diamond will wait on more mature data for its Phase II lead candidate in lung cancer.
Servier takes a Phase I rationally designed cancer candidate for $70m up front, while Black Diamond will wait on more mature data for its Phase II lead candidate in lung cancer.